보고서 요약(국문)

심장 트로포닌 시장 규모
전 세계 심장 트로포닌 시장은 2023년 41억 9천만 달러에 달했으며, 2024년부터 2031년까지 연평균 11.2%의 성장률을 보이며 2031년에는 95억 6천만 달러에 이를 것으로 예상됩니다.
심장 트로포닌 검사는 일반적으로 심장 근육 손상을 감지하는 검사입니다. 트로포닌은 심장 근육이 손상되었을 때, 예를 들어 심근경색이 발생했을 때 혈액에서 생성되는 단백질입니다. 트로포닌 수치가 상승하는 다른 원인도 있지만, 심근경색이 가장 흔한 원인입니다. 이 검사는 혈액에 정상적으로 존재하는 소량의 트로포닌은 측정하지 못합니다. 고감도 트로포닌 T(hs-TnT)는 고급 검사에 사용됩니다.
심장 트로포닌 시장 동향
전 세계 심장 트로포닌 시장의 성장은 기술 발전, 고령화 인구 증가, 심혈관 질환 환자 증가, 환자 인식 개선, 그리고 의료비 지출 증가에 의해 주도되고 있습니다.

심혈관 질환 유병률 증가가 시장 성장을 견인하고 있습니다.
심혈관 질환에 대한 인식 제고와 의료 인프라 개선이 전 세계 시장 성장을 주도하고 있습니다. 세계보건기구(WHO)에 따르면 심혈관 질환은 전 세계 사망 원인 1위입니다. 매년 약 1,790만 명이 심혈관 질환을 앓고 있으며, 심혈관 질환으로 인한 사망의 4분의 5 이상은 심근경색과 뇌졸중으로 발생하고, 이 중 3분의 1은 70세 미만에서 조기에 사망합니다. 심혈관 질환 환자 증가와 진단 필요성 증가는 시장 성장을 촉진하고 있습니다.
심장 트로포닌은 급성 관상동맥 증후군 환자의 치료 방침을 바꿀 수 있는 중요한 바이오마커로 알려져 있습니다. 트로포닌 단백질은 손상된 심장 근육에서 혈류로 방출됩니다. 최근 개발된 고감도 혈액 검사를 통해 증상 발현 직후 매우 낮은 트로포닌 수치도 조기에 검출할 수 있습니다. 심전도(ECG)는 심장의 전기적 활동을 측정하여 심근경색 시 이상 징후를 보여줄 수 있습니다.
또한, 시장 참여 기업들은 협력 및 신제품 출시와 같은 다양한 시장 전략을 적극적으로 추진하고 있습니다. 예를 들어, 2022년 6월 LumiraDx Limited는 D-Dimer 검사와 NT-proBNP 검사에 대한 CE 마크 획득으로 포트폴리오를 다각화했다고 발표했습니다. NT-proBNP 검사의 상용화는 2022년 말까지 예상되며, 임상 의사결정에 도움이 될 것으로 기대됩니다.
심장 트로포닌과 관련된 부작용은 시장 성장을 저해할 것입니다.
그러나 심장 트로포닌 또는 골격 손상과 같은 바이오마커와 관련된 제한된 특이성과 부작용은 시장 성장을 저해합니다.
COVID-19가 심장 트로포닌 시장에 미치는 영향 분석
COVID-19는 전 세계 심장 트로포닌 시장에 상당한 영향을 미쳤습니다. 2021년 10월 Nature Reviews Cardiology에 발표된 논문에 따르면, 중등도에서 중증의 COVID-19 환자에서 심혈관 합병증이 발생하며, 심장 손상 소견(트로포닌 수치 상승 및 좌심실 박출률 감소)이 관찰됩니다. 기존 심혈관 질환이 있는 환자는 COVID-19 감염에 더 취약할 수 있으며, 특히 트로포닌 T 수치가 상승한 경우 사망 위험이 증가할 수 있습니다. 이러한 환자의 사망률은 심혈관 질환이 없는 환자에 비해 최대 3배까지 높을 수 있습니다.
또한, COVID-19 환자는 심장 합병증, 특히 급성 심장 손상 및 부정맥 발생 위험이 있으며, 급성 심근 손상은 기존 심혈관 질환이 있는 환자에서 더 흔하게 발생하고 이환율 및 사망률 증가와 관련이 있습니다.
한편, 미국 심장학회(ACC)는 2020년 COVID-19 감염 환자에서 트로포닌 수치 이상 소견이 빈번하고 비특이적이라는 점을 고려하여, 임상 환경에서 급성 심근경색 진단을 평가하는 경우에만 트로포닌 수치를 측정할 것을 권고했습니다. 증거가 뒷받침되지 않는 한, 비정상적인 트로포닌 수치는 급성 심근경색의 증거로 간주되어서는 안 됩니다.
심장 트로포닌 시장 세분화 분석
현장 진단 검사(POCT) 부문은 예측 기간(2023-2030년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
유형별:
트로포닌 I
트로포닌 T
기타
검사 장소별:
임상 검사실 검사
현장 진단 검사(POCT) 부문은 가장 큰 시장 점유율을 차지합니다. 의료 기록을 위한 현장 진단 검사 시스템의 도입이 증가함에 따라 예측 기간 동안 시장 성장이 촉진될 것으로 예상됩니다. 2020년 11월 Practical Laboratory Medicine에 게재된 기사에 따르면, 인증 및 규제 표준은 환자의 전자 의료 기록에 POCT 검사 결과를 통합해야 할 필요성이 증가하고 있음을 강조합니다. 이는 POCT 결과의 접근성을 높이고, 모니터링 및 추세 분석을 가능하게 하며, 불필요한 반복 검사를 방지하고, 환자 결과에 대한 근거를 제공합니다.
POCT 결과는 임상적 의사 결정에 사용되므로 관련 참고 문헌과 함께 결과를 문서화하는 것이 중요합니다. 측정 간격, 측정 단위, 해당되는 경우 임계값, 검사 날짜 및 시간, 그리고 기기 일련 번호, 작업자 식별 번호, 시약 로트 번호, 품질 관리(QC) 결과와의 추적성을 보장해야 합니다. 또한 POCT 결과는 다른 분석 방법론으로 인한 혼동 및 추세 발생을 방지하기 위해 다른 중앙 실험실 결과와 명확하게 구분되어야 합니다. POCT는 현재 모든 병원에서 일상적으로 시행되고 있으며 다양한 의료 환경에서 환자 치료의 표준으로 자리 잡았습니다. 심장 트로포닌 검사는 POCT를 통해 정확하게 수행됩니다.
적용 분야별:
급성 관상동맥 증후군
심근 경색
울혈성 심부전
기타
최종 사용자별:
병원
진단 센터
심장 트로포닌 시장 지역별 점유율
북미 지역은 전 세계 심장 트로포닌 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
지역별:
북미
라틴 아메리카
유럽
아시아 태평양
중동 및 아프리카
북미는 심장 트로포닌 시장을 주도하고 있으며 예측 기간 동안에도 유사한 추세를 보일 것으로 예상됩니다. 시장은 다음 요인에 의해 주도됩니다. 심장 질환 진단 수요 증가 및 심장 바이오마커의 발전과 같은 요인들이 시장 성장을 견인하고 있습니다.
미국 질병통제예방센터(CDC)에 따르면 2020년 기준, 미국에서는 20세 이상 성인 약 2,010만 명(약 7.2%)이 관상동맥질환(CAD)을 앓고 있습니다. 심혈관 질환 환자 수의 증가는 해당 지역 시장의 수요 증가로 이어져 시장 성장을 촉진하고 있습니다.
또한, 시장 참여 기업들은 미국 시장에서 다양한 제품을 제공하고 있습니다. 예를 들어, Quidel Corporation은 EDTA 항응고 처리된 전혈 및 혈장 검체에서 트로포닌 I을 정량적으로 측정하는 TriageTrue™ 고감도 트로포닌 I 검사를 제공합니다. 이 검사는 Quidel의 Triage MeterPro 계측 시스템과 함께 사용하여 심근경색(MI) 진단을 보조하는 데 사용됩니다.
심장 트로포닌 시장 기업 및 경쟁 환경
심장 트로포닌 시장은 국내외 기업들이 경쟁하는 비교적 경쟁적인 시장입니다. 시장 성장에 기여하는 주요 기업으로는 Biomerieux 등이 있습니다. Beckman Coulter, Siemens Healthcare, Roche, Fujirebio, Abbott, LifeSign, Alere, Singulex 등이 주요 기업입니다. 이들 주요 업체들은 신제품 출시, 인수, 협력 등 다양한 성장 전략을 통해 전 세계 심장 트로포닌 시장의 성장에 기여하고 있습니다.

예를 들어,
2021년 4월 Roche는 Elecsys 기술을 활용하여 NT-proBNP와 고감도 심장 트로포닌 T(cTnT-hs)라는 두 가지 주요 심장 바이오마커에 대한 5가지 새로운 용도를 발표했습니다.
Biomerieux
개요:
Biomerieux는 1963년에 설립되어 프랑스에 본사를 둔 프랑스 다국적 생명공학 기업입니다. 전 세계적인 솔루션 수요를 충족하기 위해 혁신적인 제품과 서비스를 제공합니다.

제품 포트폴리오:
VIDAS 고감도 트로포닌 I: 급성 관상동맥 증후군(ACS) 관리를 최적화하는 데 유용한 도구입니다. 진단 및 치료에 높은 성능을 제공합니다. 위험도 분류를 통해 2시간 이내에 진단을 제공합니다.
글로벌 심장 트로포닌 시장 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Cardiac Troponin Market Size
The Global Cardiac Troponin Market reached US$ 4.19 billion in 2023 and is expected to reach US$ 9.56 billion by 2031, growing at a CAGR of 11.2% during the forecast period 2024-2031.
Cardiac troponin generally is a test that detects damage to the heart muscle. Troponin is a protein that occurs in the blood only when the heart muscle is damaged, as in a heart attack. Other reasons for elevated troponin exist, but a heart attack is the most familiar. The test does not measure the low amounts of troponin normally in blood. Troponin T is highly sensitive (hs-TnT) and has been used for advanced tests.
Cardiac Troponin Market Dynamics
The global cardiac troponin market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of cardiovascular patients, improving patient awareness, and rising patient healthcare expenditure.
An increasing prevalence of cardiovascular disease drives the market growth
The rising awareness of the cardiovascular disease and healthcare infrastructure drive the global market. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70. Rising patients with the disease need to diagnose the disease drives the market.
Cardiac troponin is an identified biomarker that can impact a change in the care of a patient with acute coronary syndrome. Troponin protein is released from damaged heart muscle into the bloodstream. New high-sensitivity blood tests allow the detection of a very low troponin level soon after the onset of symptoms. The electrocardiogram (ECG) measures the heart’s electrical activity and can show abnormalities in a heart attack.
In addition, the market players are adopting the market strategies such as collaboration and product launches. For instance, in June 2022, LumiraDx Limited announced the diversification of its portfolio with a CE Mark for its D-Dimer test and NT-proBNP test. The commercialization of the latter is projected by the end of 2022, which is expected to facilitate clinical decision-making.
The side effects associated with cardiac troponin will hamper the growth of the market
However, limited specificity and side effects associated with cardiac troponin or biomarkers such as skeletal injury hinder the market growth.
COVID-19 Impact Analysis on Cardiac Troponin Market
The impact of COVID-19 is significant effected on the global cardiac troponin market. As per the article published in Nature Reviews Cardiology in October 2021, cardiovascular complications in patients with moderate-to-severe COVID-19 and evidence of cardiac injury (elevated troponin levels and reduced left ventricular ejection fraction. Patients with preexisting cardiovascular disease may be more susceptible to COVID-19 infection. They may be at increased risk of death, especially when patients present with elevated troponin T levels, where mortality may be three-fold higher than those without cardiovascular disease patients.
Also, those with COVID-19 may be at risk of developing cardiac complications, especially acute cardiac injury and arrhythmias; acute myocardial injury may be more common in patients with preexisting cardiovascular disease and associated with increased morbidity and mortality.
On the other hand, according to the American College of Cardiology, in 2020, the frequency and non-specific nature of abnormal troponin results among patients with COVID-19 infection, clinicians are suggested to only measure troponin if the diagnosis of acute MI is being evaluated in clinical environments. Without supporting evidence, an abnormal troponin should not be supposed to be evidence for an acute MI.
Cardiac Troponin Market Segmentation Analysis
The point-of-care testing segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
By Type:
Troponin I
Troponin T
Others
By Location of Testing:
Laboratory Testing
Point of Care Testing
The point of care testing segment accounts for the largest market share. The rising adoption of point-of-care testing systems for health records is expected to boost the market over the forecast period. As per the article published in Practical Laboratory Medicine in November 2020, Accreditation and regulatory standards highlight the rising need to integrate POC Testing results into the patient’s electric medical records. This promotes accessibility of POCT results, the ability to monitor and trend, prevents unnecessary repeat testing and provides evidence for patient outcomes.
As POCT results are used to make clinical decisions, it is important to document results with associated reference intervals, units of measurement, critical values if applicable, date and time of testing, and also be traceable to device serial number, operator identification number, reagent lot number, and quality control (QC) results. POCT results should also be clearly differentiated from other central laboratory results to avoid confusion and trending results from different analytical methodologies. POCT is currently routine in all hospitals and has become the standard for patient care in a variety of other healthcare settings. Cardiac troponin is accurately performed by POCT.
By Application:
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others
By End User:
Hospitals
Diagnostic Centers
Cardiac Troponin Market Geographical Share
North America region holds the largest market share of the global cardiac troponin market
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East and Africa
North America dominates the market for cardiac troponin and is expected to show a similar trend over the forecast period. The market is driven by the factors such as increasing demand for diagnosis of cardiac disease and advancements in cardiac biomarkers.
As per the Centers for Disease Control and Prevention, 2020, in the United States about 20.1 million adults age 20 and older have CAD (about 7.2%). The rising the patients with cardiovascular disease leads to increasing demand for the market in the region which drives the market in the region.
In addition, the market players are offers the products in the United States region. For instance, Quidel Corporation provides TriageTrueTM High Sensitivity Troponin I Test for the quantitative determination of troponin I in EDTA anticoagulated whole blood and plasma specimens. The test is to be indicated as an aid in the diagnosis of myocardial infarction (MI) for use with Quidel’s Triage MeterPro instrumented system.
Cardiac Troponin Market Companies and Competitive Landscape
The cardiac troponin market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Biomerieux, Beckman Coulter, Siemens Healthcare, Roche, Fujirebio, Abbott, LifeSign, Alere, and Singulex, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the cardiac troponin market globally.
For instance,
In April 2021, Roche announced a series of five new intended uses for two key cardiac biomarkers (cTnT-hs), using the Elecsys technology, which has the NT-proBNP and highly sensitive cardiac troponin T.
Biomerieux
Overview:
Biomerieux is a French multinational biotechnology organization founded in 1963 and headquartered in France. It offers innovative products and services to meet the need for global solutions.
Product Portfolio:
VIDAS High sensitive Troponin I: It is a useful aid to optimize the management of Acute Coronary Syndromes (ACS). It provides a high level of performance for diagnosis and risk stratification and delivers a diagnosis within 2 hours.
The global Cardiac Troponin market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

상세 목차

1. Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising demand for cardiac biomarkers to diagnose cardiovascular diseases
4.1.1.2. Rising prevalence of acute coronary syndrome
4.1.2. Restraints:
4.1.2.1. Lack of required precision for collecting samples
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Troponin I*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
7.3. Troponin T
8. By Location of Testing
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
8.1.2. Market Attractiveness Index, By Location of Testing
8.2. Laboratory Testing*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
8.3. Point of Care Testing
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Acute Coronary Syndrome*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
9.3. Myocardial Infarction
9.4. Congestive Heart Failure
9.5. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
10.3. Diagnostic Centers
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
13. Company Profiles
13.1. Biomerieux*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Beckman Coulter
13.3. Siemens Healthcare
13.4. Roche
13.5. Fujirebio
13.6. Abbott
13.7. LifeSign
13.8. Alere
13.9. Singulex(*LIST NOT EXHAUSTIVE)
14. DataM Intelligence
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us

언급된 주요 기업들

Biomerieux, Beckman Coulter, Siemens Healthcare, Roche, Fujirebio, Abbott, LifeSign, Alere

표 목록 (Tables)

List of Tables Table 01 Global Cardiac Troponin Market Value, By Type, 2021, 2025 & 2029 ($ Million)

Table 02 Global Cardiac Troponin Market Value, By Location of Testing, 2021, 2025 & 2029 ($ Million)

Table 03 Global Cardiac Troponin Market Value, By Application, 2021, 2025 & 2029 ($ Million)

Table 04 Global Cardiac Troponin Market Value, By End User, 2021, 2025 & 2029 ($ Million)

Table 05 Global Cardiac Troponin Market Value, By Region, 2021, 2025 & 2029 ($ Million)

Table 06 Global Cardiac Troponin Market Value, By Type, 2021, 2025 & 2029 ($ Million)

Table 07 Global Cardiac Troponin Market Value, By Type, 2020-2029 ($ Million)

Table 08 Global Cardiac Troponin Market Value, By Location of Testing, 2021, 2025 & 2029 ($ Million)

Table 09 Global Cardiac Troponin Market Value, By Location of Testing, 2020-2029 ($ Million)

Table 10 Global Cardiac Troponin Market Value, By Application, 2021, 2025 & 2029 ($ Million)

Table 11 Global Cardiac Troponin Market Value, By Application, 2020-2029 ($ Million)

Table 12 Global Cardiac Troponin Market Value, By End User, 2021, 2025 & 2029 ($ Million)

Table 13 Global Cardiac Troponin Market Value, By End User, 2020-2029 ($ Million)

Table 14 Global Cardiac Troponin Market Value, By Region, 2021, 2025 & 2029 ($ Million)

Table 15 Global Cardiac Troponin Market Value, By Region, 2020-2029 ($ Million)

Table 16 North America Cardiac Troponin Market Value, By Type, 2020-2029 ($ Million)

Table 17 North America Cardiac Troponin Market Value, By Location of Testing, 2020-2029 ($ Million)

Table 18 North America Cardiac Troponin Market Value, By Application, 2020-2029 ($ Million)

Table 19 North America Cardiac Troponin Market Value, By End User, 2020-2029 ($ Million)

Table 20 North America Cardiac Troponin Market Value, By Country, 2020-2029 ($ Million)

Table 21 South America Cardiac Troponin Market Value, By Type, 2020-2029 ($ Million)

Table 22 South America Cardiac Troponin Market Value, By Location of Testing, 2020-2029 ($ Million)

Table 23 South America Cardiac Troponin Market Value, By Application, 2020-2029 ($ Million)

Table 24 South America Cardiac Troponin Market Value, By End User, 2020-2029 ($ Million)

Table 25 South America Cardiac Troponin Market Value, By Country, 2020-2029 ($ Million)

Table 26 Europe Cardiac Troponin Market Value, By Type, 2020-2029 ($ Million)

Table 27 Europe Cardiac Troponin Market Value, By Location of Testing, 2020-2029 ($ Million)

Table 28 Europe Cardiac Troponin Market Value, By Application, 2020-2029 ($ Million)

Table 29 Europe Cardiac Troponin Market Value, By End User, 2020-2029 ($ Million)

Table 30 Europe Cardiac Troponin Market Value, By Country, 2020-2029 ($ Million)

Table 31 Asia-Pacific Cardiac Troponin Market Value, By Type, 2020-2029 ($ Million)

Table 32 Asia-Pacific Cardiac Troponin Market Value, By Location of Testing, 2020-2029 ($ Million)

Table 33 Asia-Pacific Cardiac Troponin Market Value, By Application, 2020-2029 ($ Million)

Table 34 Asia-Pacific Cardiac Troponin Market Value, By End User, 2020-2029 ($ Million)

Table 35 Asia-Pacific Cardiac Troponin Market Value, By Country, 2020-2029 ($ Million)

Table 36 Middle East & Africa Cardiac Troponin Market Value, By Type, 2020-2029 ($ Million)

Table 37 Middle East & Africa Cardiac Troponin Market Value, By Location of Testing, 2020-2029 ($ Million)

Table 38 Middle East & Africa Cardiac Troponin Market Value, By Application, 2020-2029 ($ Million)

Table 39 Middle East & Africa Cardiac Troponin Market Value, By End User, 2020-2029 ($ Million)

Table 40 Biomerieux : Overview

Table 41 Biomerieux : Product Portfolio

Table 42 Biomerieux : Key Developments

Table 43 Beckman Coulter: Overview

Table 44 Beckman Coulter: Product Portfolio

Table 45 Beckman Coulter: Key Developments

Table 46 Siemens Healthcare: Overview

Table 47 Siemens Healthcare: Product Portfolio

Table 48 Siemens Healthcare: Key Developments

Table 49 Roche: Overview

Table 50 Roche: Product Portfolio

Table 51 Roche: Key Developments

Table 52 Fujirebio: Overview

Table 53 Fujirebio: Product Portfolio

Table 54 Fujirebio: Key Developments

Table 55 Abbott: Overview

Table 56 Abbott: Product Portfolio

Table 57 Abbott: Key Developments

Table 58 LifeSign: Overview

Table 59 LifeSign: Product Portfolio

Table 60 LifeSign: Key Developments

Table 61 Alere: Overview

Table 62 Alere: Product Portfolio

Table 63 Alere: Key Developments

Table 64 Singulex: Overview

Table 65 Singulex: Product Portfolio

Table 66 Singulex: Key Developments

그림 목록 (Figures)

List of Figures Figure 01 Global Cardiac Troponin Market Share, By Type, 2020 & 2029 (%)

Figure 02 Global Cardiac Troponin Market Share, By Location of Testing, 2020 & 2029 (%)

Figure 03 Global Cardiac Troponin Market Share, By Application, 2020 & 2029 (%)

Figure 04 Global Cardiac Troponin Market Share, By End User, 2020 & 2029 (%)

Figure 05 Global Cardiac Troponin Market Share, By Region, 2020 & 2029 (%)

Figure 06 Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 07 Global Cardiac Troponin Market Y-o-Y Growth, By Type, 2020-2029 (%)

Figure 08 Troponin I: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 09 Troponin T: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 10 Global Cardiac Troponin Market Y-o-Y Growth, By Location of Testing, 2020-2029 (%)

Figure 11 Laboratory Testing: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 12 Point of Care Testing: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 13 Global Cardiac Troponin Market Y-o-Y Growth, By Application, 2020-2029 (%)

Figure 14 Acute Coronary Syndrome: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 15 Myocardial Infarction: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 16 Congestive Heart Failure: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 17 Others: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 18 Global Cardiac Troponin Market Y-o-Y Growth, By End User, 2020-2029 (%)

Figure 19 Hospitals: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 20 Diagnostic Centers: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 21 Others: Global Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 22 Global Cardiac Troponin Market Y-o-Y Growth, By Region, 2020-2029 (%)

Figure 23 North America Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 24 North America Cardiac Troponin Market Share, By Type, 2020 & 2029 (%)

Figure 25 North America Cardiac Troponin Market Share, By Location of Testing, 2020 & 2029 (%)

Figure 26 North America Cardiac Troponin Market Share, By Application, 2020 & 2029 (%)

Figure 27 North America Cardiac Troponin Market Share, By End User, 2020 & 2029 (%)

Figure 28 North America Cardiac Troponin Market Share, By Country, 2020 & 2029 (%)

Figure 29 South America Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 30 South America Cardiac Troponin Market Share, By Type, 2020 & 2029 (%)

Figure 31 South America Cardiac Troponin Market Share, By Location of Testing, 2020 & 2029 (%)

Figure 32 South America Cardiac Troponin Market Share, By Application, 2020 & 2029 (%)

Figure 33 South America Cardiac Troponin Market Share, By End User, 2020 & 2029 (%)

Figure 34 South America Cardiac Troponin Market Share, By Country, 2020 & 2029 (%)

Figure 35 Europe Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 36 Europe Cardiac Troponin Market Share, By Type, 2020 & 2029 (%)

Figure 37 Europe Cardiac Troponin Market Share, By Location of Testing, 2020 & 2029 (%)

Figure 38 Europe Cardiac Troponin Market Share, By Application, 2020 & 2029 (%)

Figure 39 Europe Cardiac Troponin Market Share, By End User, 2020 & 2029 (%)

Figure 40 Europe Cardiac Troponin Market Share, By Country, 2020 & 2029 (%)

Figure 41 Asia-Pacific Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 42 Asia-Pacific Cardiac Troponin Market Share, By Type, 2020 & 2029 (%)

Figure 43 Asia-Pacific Cardiac Troponin Market Share, By Location of Testing, 2020 & 2029 (%)

Figure 44 Asia-Pacific Cardiac Troponin Market Share, By Application, 2020 & 2029 (%)

Figure 45 Asia-Pacific Cardiac Troponin Market Share, By End User, 2020 & 2029 (%)

Figure 46 Asia-Pacific Cardiac Troponin Market Share, By Country, 2020 & 2029 (%)

Figure 47 Middle East & Africa Cardiac Troponin Market Value, 2020-2029 ($ Million)

Figure 48 Middle East & Africa Cardiac Troponin Market Share, By Type, 2020 & 2029 (%)

Figure 49 Middle East & Africa Cardiac Troponin Market Share, By Location of Testing, 2020 & 2029 (%)

Figure 50 Middle East & Africa Cardiac Troponin Market Share, By Application, 2020 & 2029 (%)

Figure 51 Middle East & Africa Cardiac Troponin Market Share, By End User, 2020 & 2029 (%)

Figure 52 Biomerieux : Financials

Figure 53 Beckman Coulter: Financials

Figure 54 Siemens Healthcare: Financials

Figure 55 Roche: Financials

Figure 56 Fujirebio: Financials

Figure 57 Abbott: Financials

Figure 58 LifeSign: Financials

Figure 59 Alere: Financials

Figure 60 Singulex: Financials

글로벌 심장 트로포닌 시장 – 2024-2031

Global Cardiac Troponin Market - 2024-2031